Special Issue

Diagnosis and Therapeutic Management of Gastrointestinal Cancers: 2nd Edition

Message from the Guest Editors

Gastrointestinal cancers have rising incidence and mortality rates worldwide and are responsible for 4.8 million new cancer cases and 3.4 million cancer-related deaths per year (WHO 2018). In addition to advances in the combination of conventional chemotherapy with targeted treatment options and the developing realm of immunotherapy, novel strategies for tumor treatment have yielded remarkable benefits for patients. Translational and clinical research has led to the introduction of targeted immune and/or chemotherapy regimens, while advancements in new surgical technology have led to a significant reduction in morbidity and demonstrated increasingly promising results in the recent past. Despite the observation of new advancements, challenges still remain, including issues related to preventive measures, healthcare, and reimbursement. This issue of Cancers will cover some of the topics related to the diagnosis and therapeutic management of gastrointestinal cancers by publishing reviews and/or meta-analyses, as well as recent results from original research.

Guest Editors

Prof. Dr. Christian Sebesta

Klinik Floridsdorf Wiener Gesundheitsverbund, Vienna, Austria

Prof. Dr. Harald Rosen

Faculty of Medicine, Sigmund Freud University, Vienna, Austria

Deadline for manuscript submissions

20 December 2025



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/234642

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

